Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 12, 2019 (7 years ago)

Paclitaxel 258 Mg / 500 Ml Ns Ivpb

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

PACLITAXEL 258 MG / 500 ML NS IVPB; PACLITAXEL 318 MG / 500 ML NS IVPB; PACLITAXEL 385 MG / 500 ML NS IVPB; PACLITAXEL 340 MG / 500 ML NS IVPB; PACLITAXEL 332 MG / 500 ML NS IVPB; PACLITAXEL 250 MG / 500 ML NS IVPB; PACLITAXEL 117 MG / 250 ML NACL 0.9% IVPB PACLITAXEL 90 MG / 250 ML NS IVPB; PACLITAXEL 290 MG / 500 ML NS IVPB; PACLITAXEL 168 MG / 250 ML NS IVPB; PACLITAXEL 157 MG / 250 ML NS IVPB; PACLITAXEL 350 MG / 500 ML NS IVPB; PACLITAXEL 280 mg / 500 ML NS IVPB; PACLITAXEL 282 mg / 500 ML NS IVPB; PACLITAXEL 90 MG / 250 ML D5W IVPB; PACLITAXEL 255 MG / 500 ML NS IVPB; PACLITAXEL 100 MG / 250 ML NS IVPB; PACLITAXEL 80 MG / 250 ML D5W IVPB; PACLITAXEL 117 MG / 250 ML NS IVPB; PACLITAXEL 159 MG / 250 ML NS IVPB; PACLITAXEL 330 MG / 500 ML NS IVPB; PACLITAXEL135 MG / 250 ML NS IVPB; PACLITAXEL 200 MG / 500 ML NS IVPB; PACLITAXEL 150 MG / 250 ML NS IVPB; PACLITAXEL 130 MG / 250 ML NS IVPB; PACLITAXEL 144 MG / 250 ML NS IVPB; PACLITAXEL 300 MG / 500 ML NS IVPB; PACLITAXEL 120 MG / 250 ML NS IVPB; PACLITAXEL 140 MG / 250 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Drug: Paclitaxel

Recalling firm
Infusion Options, Inc.
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1798-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Paclitaxel recalls

See all
Class II · Moderate risk

Paclitaxel Semi-Synthetic active pharmaceutical ingredient…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-829-2015
Class III · Low risk

Paclitaxel Injection

Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-763-50 D-016-2014
Class II · Moderate risk

Paclitaxel Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. D-1682-2012

Other recalls by Infusion Options, Inc.

All 2019 recalls